Suppr超能文献

半时间 PDT 对慢性中心性浆液性脉络膜视网膜病变患者视网膜敏感性的长期影响。

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.

机构信息

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan.

出版信息

Biomed Res Int. 2020 Aug 17;2020:3190136. doi: 10.1155/2020/3190136. eCollection 2020.

Abstract

The purpose of this study was to evaluate the long-term effects of half-time photodynamic therapy (PDT) on the retinal sensitivity in eyes with chronic central serous chorioretinopathy (CSC). Twenty-two eyes of 22 patients with chronic CSC were studied. PDT was applied with full-dose verteporfin and half-time laser duration. The best-corrected visual acuity (BCVA) and retinal sensitivity in the central 2 and 10 degrees were evaluated at the baseline, and at 12 and 24 months after the half-time PDT. The retinal sensitivity was determined by Macular Integrity Assessment microperimetry (MAIA, Centervue, Padova, Italy). The results showed that the mean retinal sensitivities in the central 2 and 10 degrees were significantly improved at 12 months (25.6 ± 2.79 dB, median; 26.11 dB, 25.6 ± 2.25 dB, median; 25.65 dB, respectively; < 0.001) and at 24 months (26.3 ± 2.62 dB, median; 27.38 dB, 26.6 ± 2.21 dB, median; 27.45 dB, respectively; < 0.001) after the treatment compared to that at the baseline (19.2 ± 3.93 dB, median; 19.34 dB, 20.9 ± 2.92 dB, median; 20.9 dB, respectively). The BCVA was also significantly improved from 0.18 ± 0.19 median; 0.15 logarithm of the minimum angle of resolution (logMAR) units at the baseline to 0.07 ± 0.15 median; 0 logMAR units at 12 months ( < 0.001) and to 0.049 ± 0.16 median; -0.039 logMAR units at 24 months ( < 0.001). We conclude that half-time PDT results in a significant improvement of the mean central retinal sensitivity for at least 24 months in eyes with chronic CSC. Thus, half-time PDT is beneficial in resolving chronic CSC for a relatively long period.

摘要

本研究旨在评估半量时的光动力疗法(PDT)对慢性中心性浆液性脉络膜视网膜病变(CSC)患者视网膜敏感性的长期影响。研究共纳入 22 例(22 只眼)慢性 CSC 患者。给予全剂量维替泊芬和半量激光持续时间的 PDT。在基线、半量 PDT 后 12 个月和 24 个月评估最佳矫正视力(BCVA)和中央 2 度和 10 度的视网膜敏感性。使用黄斑完整性评估微视野计(MAIA,Centervue,帕多瓦,意大利)来评估视网膜敏感性。结果显示,治疗后 12 个月(25.6±2.79dB,中位数;26.11dB,25.6±2.25dB,中位数;25.65dB)和 24 个月(26.3±2.62dB,中位数;27.38dB,26.6±2.21dB,中位数;27.45dB)时,中央 2 度和 10 度的平均视网膜敏感性较基线时显著提高(19.2±3.93dB,中位数;19.34dB,20.9±2.92dB,中位数;20.9dB)(均<0.001)。BCVA 也从基线时的 0.18±0.19 中位数;0.15 最小分辨角对数(logMAR)单位改善至治疗后 12 个月时的 0.07±0.15 中位数;0 logMAR 单位(<0.001)和治疗后 24 个月时的 0.049±0.16 中位数;-0.039 logMAR 单位(<0.001)。我们的结论是,半量 PDT 可使慢性 CSC 患者的平均中央视网膜敏感性至少在 24 个月内显著提高。因此,半量 PDT 对慢性 CSC 的缓解作用可持续较长时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d50/7450301/152ff7506ed4/BMRI2020-3190136.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验